Delving into the Latest Updates on Jiangsu Sihuan Bioengineering Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Neoplasms

Digestive System Disorders

Colony-stimulating factors

Small molecule drug

Interleukins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Neoplasms	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
Colony-stimulating factors	2
Interleukins	1

Top 5 Target	Count

EPO receptor(Erythropoietin receptor)	1
CSF-3R(Colony stimulating factor 3 receptor)	1
IL-2R(Interleukin-2 receptor)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

4

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.) ( CSF-3R )	Neutropenia More	Approved
Recombinant human interleukin-2(Beijing Four Rings Biopharmaceutical Co. Ltd.) ( IL-2R )	Melanoma More	Approved
Methylcantharidimide	Liver Cancer More	Approved
Recombinant human erythropoietin(Beijing Four Rings Biopharmaceutical Co. Ltd.) ( EPO receptor )	Anemia More	Approved
Menadiol Sodium Diphosphate	Biliary Fistula More	Phase 1